---
search:
  boost: 3
---

# Oral Anticoagulants

This is a subcategory of Blood Formation, Coagulation, and Thrombosis Agents.

## Decision Tree

- [Oral Anticoagulants- Non-Preferred - Savaysa, Xarelto Suspension, Dabigatran(Pradaxa (P, BvG))](https://forms.office.com/Pages/ResponsePage.aspx?id=nPhjxpvvj0G9PUHkbAzgaN9UYz8EqmlIs3_TYn4TbXBUMldPQklWQlQxSkJXWldUWUxVQUwyTUo2NiQlQCN0PWcu){ :target="_blank" rel="noopener"}

## Formulary

### Preferred

| Preferred                                   | Generic Name                               | Quantity | Time (Days) |
|:--------------------------------------------|:-------------------------------------------|:--------:|:-----------:|
| Eliquis <sup>AR</sup>                                    |                                            |          |             |
| Pradaxa <sup>AR, BvG ==(Process by NDC)==</sup> |                                            |          |             |
| Pradaxa Pellet Pak <sup>AR</sup>                          |                                            |          |             |
| Warfarin <sup>AR</sup>                                    |                                            |          |             |
| Xarelto Suspension <sup>AR</sup>                          |                                            |          |             |
| Xarelto Tab <sup>AR, QL</sup>                   | Rivaroxaban Tab (all strengths excl 15 MG) |   102    |     102     |
| Xarelto Tab <sup>AR, QL</sup>                   | Rivaroxaban Tab 15 MG                      |   204    |     102     |

### Non-Preferred

| Non-Preferred                                                                         | Generic Name | Quantity | Time (Days) |
|:--------------------------------------------------------------------------------------|:-------------|:--------:|:-----------:|
| <span title = "Brand Preferred: Pradaxa">Dabigatran</span> <sup>AR, Brand Preferred</sup> |              |          |             |
| Savaysa <sup>AR</sup>                                                                               |              |          |             |
| Xarelto Susp <sup>AR</sup>                                                                          |              |          |             |

## Authorizations

**Length of Authorizations**: 365 days

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least ^^14 days^^ with at least ^^two preferred^^ drugs
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

**AR** â€“ All drugs: a PA is required for patients older than 12 years old


## Links

[Denial Language (Rph Use Only: Technicians CANNOT deny Prior Authorizations)](https://mygainwell-my.sharepoint.com.mcas.ms/:w:/r/personal/rachel_carpenter_gainwelltechnologies_com/_layouts/15/Doc.aspx?sourcedoc=%7BCD777F63-7F18-4713-8D6A-B043BEE631F5%7D&file=Denial%20Language%20Updated%2009112023.docx&action=embedview&mobileredirect=true&wdStartOn=11&cid=f4472ece-6d4f-4694-b0c5-c150a2f53fea){ :target="_blank" rel="noopener"}

[Criteria](https://medicaid.ohio.gov/static/PHM/drug-coverage/20231001+UPDL+Criteria+_v2.FINAL.pdf#page=17){ :target="_blank" rel="noopener"}

[Preferred Drug List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20231001_UPDL_V2.FINAL.hyperlinks_added.pdf#page=10){ :target="_blank" rel="noopener"}

[Quantity Limit List](https://medicaid.ohio.gov/static/PHM/drug-coverage/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf){ :target="_blank" rel="noopener"}
